Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - cetuximab, quantity: 5 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid monohydrate; water for injections; sodium chloride; sodium hydroxide; glycine; polysorbate 80 - erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer. in combination with infusional 5-fluorouracil/folinic acid plus irinotecan. in combination with irinotecan in patients who are refractory to first-line chemotherapy. in first-line in combination with folfox. as a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy. (see clinical trials) erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. in combination with radiation therapy for locally advanced disease. in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - cetuximab, quantity: 5 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; citric acid monohydrate; polysorbate 80; sodium chloride; sodium hydroxide; glycine - erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer. in combination with infusional 5-fluorouracil/folinic acid plus irinotecan. in combination with irinotecan in patients who are refractory to first-line chemotherapy. in first-line in combination with folfox. as a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy. (see clinical trials) erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. in combination with radiation therapy for locally advanced disease. in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - olive oil, quantity: 32 g/l; soya oil, quantity: 8 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; water for injections; sodium hydroxide; egg lecithin; nitrogen; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; egg lecithin; water for injections; glycerol; nitrogen; sodium hydroxide - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: water for injections; nitrogen; sodium hydroxide; sodium oleate; glycerol; egg lecithin - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: egg lecithin; sodium oleate; sodium hydroxide; glycerol; water for injections; nitrogen - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; nitrogen; egg lecithin; glycerol; sodium oleate - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - pralatrexate, quantity: 20 mg/ml - injection, intravenous infusion - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - folotyn is indicated for the treatment of adult patients with peripheral t-cell lymphoma (nodal, extranodal, and leukaemic/disseminated) who have progressed after at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - pralatrexate, quantity: 20 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - folotyn is indicated for the treatment of adult patients with peripheral t-cell lymphoma (nodal, extranodal, and leukaemic/disseminated) who have progressed after at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: egg lecithin; glycerol; sodium oleate; water for injections; sodium hydroxide; dl-alpha-tocopherol - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.